News

Biotherapeutics company aTyr Pharma, Inc. was recently awarded orphan drug designation from the European Commission (EC) for its Resolaris therapy, designed to treat facioscapulohumeral muscular dystrophy (FSHD). The investigational drug is the company’s first Physiocrine-based therapy, and is currently being developed to become a first-in-class intravenous protein treatment for…

ReveraGen BioPharma recently announced the start of a Phase 1 clinical trial of a new disassociate steroidal drug called VBP15, indicated to address Duchenne muscular dystrophy (DMD). Recruitment for the trial is currently underway, and the initial doses have already been administered in the first volunteers. “Glucocorticoids are a…

Researchers at Duke University recently revealed an approach to gene therapy that has the potential to treat more than half of the patients with Duchenne Muscular Dystrophy (DMD). The study was published in the journal Nature Communications and is entitled “…

In a recent study entitled “Progression of cardiac involvement in patients with limb-girdle type 2 and Becker muscular dystrophies: A 9-year follow-up study,” researchers describe a higher risk for cardiac dysfunction in patients suffering from Becker muscular dystrophy and limb-girdle muscular dystrophy, particularly subtypes 2I and 2E.

Researchers working in public health have recently published a report based on the first broad study in the United States on the frequency of two common muscle-weakness disorders that mostly affect boys: Duchenne muscular dystrophy and Becker muscular dystrophy. The study was published in …

Britain is now the first country in the world that allows the fusion of DNA from three people for the creation of babies. This could provide a solution for preventing diseases such as muscular dystropy, a hereditary disease characterized by progressive weakening of the muscles. The decision involved a change to in vitro fertilization…

Parent Project Muscular Dystrophy (PPMD), a nonprofit organization fighting against Duchenne muscular dystrophy (Duchenne) recently designated the University of Iowa Children’s Hospital (UI Children’s Hospital) a Certified Duchenne Care Center. UI Children’s Hospital is now the 7th center certified by PPMD, and is recognized for its dedication to improving care…

A new pilot clinical trial on Duchenne Muscular Dystrophy, entitled “Double Push Acoustic Radiation Force (DP ARF) Ultrasound for Monitoring Muscle Degeneration in Duchenne Muscular Dystrophy,” is now enrolling participants. The trial is a prospective observational study to test the capacity of a new ultrasound-based imaging…

The Muscular Dystrophy Association (MDA) and Lowe’s stores are joining efforts to launch the MDA’s Shamrock program, the largest St. Patrick’s Day philanthropic event dedicated to help patients who live with the disabling muscle disease Duchenne muscular dystrophy. The FORTUNE 100 home improvement…

A recent study was published in The Lancet Neurology journal showing that a specific cardiac drug is able to induce cardiac function improvement in boys with muscular dystrophy and cardiomyopathy. The study is entitled “Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a…